Milsaperidone (VHX-896) vs Risperidone (Risperdal Consta)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Risperidone (Risperdal Consta)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule
Reliable signal

NCT00253136 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 458 participants, using change in a standard psychiatric symptom scale as the primary measure. The FDA product label for this pivotal trial reports that 47% of patients on the 25 mg dose showed a clinically meaningful improvement, compared with 17% on placebo.

Reported efficacy

Change from baseline to the end of double-blind treatment in the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) total score: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly. (met)

Result source: NCT00253136

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Risperidone (Risperdal Consta)
PANSS total, change—Not reported-9.3 vs -1.1vs Quetiapinewk 104 · n 326NCT00216476
1 other result
  • -11.7 vs -13 wk 52 · n 17 · Phase 4 · secondary NCT00992407
CGI-S, change—Not reported-0.3 vs 0.1vs Quetiapinewk 104 · n 326NCT00216476
1 other result
  • -0.6 vs -0.7 wk 52 · n 17 · Phase 4 · secondary NCT00992407
PANSS response—Not reported—Not posted · NCT00216580
PSP, change—Not reported5.3 vs 6.0vs Risperidone Tabletswk 52 · n 17NCT00992407
Relapse (% of patients)—Not reported5% vs 32.6%vs Risperidonewk 52 · n 40NCT00330551
1 other result
  • 34.4% vs 16.1% wk 104 · n 32 · Phase 4 · secondary NCT00246259

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal Consta)
-9.3 vs -1.1vs Quetiapinewk 104 · n 326NCT00216476
1 other result
  • -11.7 vs -13 wk 52 · n 17 · Phase 4 · secondary NCT00992407

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal Consta)
-0.3 vs 0.1vs Quetiapinewk 104 · n 326NCT00216476
1 other result
  • -0.6 vs -0.7 wk 52 · n 17 · Phase 4 · secondary NCT00992407

PANSS response

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal Consta)
—Not posted · NCT00216580

PSP, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal Consta)
5.3 vs 6.0vs Risperidone Tabletswk 52 · n 17NCT00992407

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal Consta)
5% vs 32.6%vs Risperidonewk 52 · n 40NCT00330551
1 other result
  • 34.4% vs 16.1% wk 104 · n 32 · Phase 4 · secondary NCT00246259
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Risperidone (Risperdal Consta): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRisperidone (Risperdal Consta)
Dropout rate
38.4%a
NCT00132314 · Phase 3
show 14 more results
5.9%CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
0%CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
14.3%HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
5.9%HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
25%Long-acting Injectable Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
—Long-acting Injectible Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
29.5%
NCT00539071 · Phase 4 · registry result, not featured evidence
83.8%
NCT00992407 · Phase 4 · registry result, not featured evidence
26.5%
NCT00130923 · Phase 4 · registry result, not featured evidence
31.8%
NCT00216671 · Phase 4 · registry result, not featured evidence
63.6%
NCT00246259 · Phase 4 · registry result, not featured evidence
67.5%
NCT00269919 · Phase 4 · registry result, not featured evidence
45.3%
NCT01726335 · Phase 4 · registry result, not featured evidence
31.9%
NCT00216476 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00132314 · Phase 3
show 14 more results
—CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
—CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
—HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—Long-acting Injectable Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
—Long-acting Injectible Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
—
NCT00539071 · Phase 4 · registry result, not featured evidence
18.9%
NCT00992407 · Phase 4 · registry result, not featured evidence
—
NCT00130923 · Phase 4 · registry result, not featured evidence
5.5%
NCT00216671 · Phase 4 · registry result, not featured evidence
11.4%
NCT00246259 · Phase 4 · registry result, not featured evidence
—
NCT00269919 · Phase 4 · registry result, not featured evidence
7.5%
NCT01726335 · Phase 4 · registry result, not featured evidence
1.8%
NCT00216476 · Phase 3 · registry result, not featured evidence
Serious AEs
51.3%a
NCT00132314 · Phase 3
show 14 more results
18.8%CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
8.3%CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
8.3%HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
0%HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—Long-acting Injectable Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
5%Long-acting Injectible Risperidone
NCT00330551 · Phase 4 · registry result, not featured evidence
6.4%
NCT00539071 · Phase 4 · registry result, not featured evidence
0%
NCT00992407 · Phase 4 · registry result, not featured evidence
32.7%
NCT00130923 · Phase 4 · registry result, not featured evidence
16.4%
NCT00216671 · Phase 4 · registry result, not featured evidence
4.5%
NCT00246259 · Phase 4 · registry result, not featured evidence
15.4%
NCT00269919 · Phase 4 · registry result, not featured evidence
5.7%
NCT01726335 · Phase 4 · registry result, not featured evidence
19.1%
NCT00216476 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
insomnia 18.7%
headache 17.1%
vomiting 13.9%
NCT00132314 · Phase 3
show 13 more results
bmi increase normal/overweight to obese 31.3%
ldl or triglyceride increase 25%
prolactin related symptom 12.5%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase normal/overweight to obese 25%
prolactin related symptom 16.7%
ldl or triglyceride increase 8.3%
NCT00333177 · Phase 4 · registry result, not featured evidence
ldl or triglyceride increase 41.7%
prolactin related symptom 16.7%
bmi increase normal/overweight to obese 0%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase normal/overweight to obese 12.5%
ldl or triglyceride increase 6.3%
prolactin related symptom 6.3%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase from normal or overweight to obese 17.5%
prolactin related 7.5%
lipid increase 5%
NCT00330551 · Phase 4 · registry result, not featured evidence
non-serious adverse events 16.7%
NCT00539071 · Phase 4 · registry result, not featured evidence
akathisisa 10%
anxiety 10%
muscle rigidity 10%
NCT00992407 · Phase 4 · registry result, not featured evidence
insomnia 10.2%
pain 10.2%
vomiting 10.2%
NCT00130923 · Phase 4 · registry result, not featured evidence
insomnia 8.2%
akathisia 7.3%
weight increased 7.3%
NCT00216671 · Phase 4 · registry result, not featured evidence
headache 34.1%
insomnia 29.5%
fatigue 25%
NCT00246259 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 20.5%
akathisia 12.8%
vision blurred 10.3%
NCT00269919 · Phase 4 · registry result, not featured evidence
libido decreased 22.6%
weight increased 13.2%
blood prolactin increased 11.3%
NCT01726335 · Phase 4 · registry result, not featured evidence
hyperprolactinaemia 13.1%
anxiety 11.9%
insomnia 10.9%
NCT00216476 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Risperidone (Risperdal Consta)

Hospitalization-free Survival NA vs 23.64 Oral Antipsychotic months
time to event · months
NCT00132314 · Phase 3
MCCB Composite 6.7 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00333177 · Phase 4 · registry result, not featured evidence
show 3 more results
0.9 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
3.9 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
5.9 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
Gfs Role 2.9 score @ 26wk
absolute change · score
No placebo or comparator arm
NCT00333177 · Phase 4 · registry result, not featured evidence
show 7 more results
0.92 score @ 26wk
NCT00333177 · Phase 4 · registry result, not featured evidence
1.27 score @ 26wk
NCT00333177 · Phase 4 · registry result, not featured evidence
-0.82 score @ 26wk
NCT00333177 · Phase 4 · registry result, not featured evidence
2.7 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
1.69 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
2.43 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
0.18 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
WBI Quality Work/School Performance -6.5 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00333177 · Phase 4 · registry result, not featured evidence
show 3 more results
8.8 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
-3.4 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
0 score @ 52wk
NCT00333177 · Phase 4 · registry result, not featured evidence
Relapse 7.1% (n=28)
event count · % of participants
No placebo or comparator arm
NCT00333177 · Phase 4 · registry result, not featured evidence · converted to % from 2 participants as posted
show 1 more result
35.7% (n=28)*
NCT00333177 · Phase 4 · registry result, not featured evidence · converted to % from 10 participants as posted
Relapse 5% (n=40) vs 32.6% (n=43) Risperidone @ 52wk
event count · % of participants
NCT00330551 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
show 1 more result
34.4% (n=32) vs 16.1% (n=31) Oral Antipsychotic @ 104wk
NCT00246259 · Phase 4 · registry result, not featured evidence
MCCB Composite 3.5 vs 4.4 Risperidone score @ 52wk
absolute change · score
NCT00330551 · Phase 4 · registry result, not featured evidence
SUMD Total 0.07 vs -0.24 Risperidone score @ 52wk
absolute change · score
NCT00330551 · Phase 4 · registry result, not featured evidence
show 1 more result
-4.8 vs -3.5 Risperidone Tablets score @ 52wk
NCT00992407 · Phase 4 · registry result, not featured evidence
PANSS Total 80.8 score @ 6wk
absolute change · score
No placebo or comparator arm
NCT00539071 · Phase 4 · registry result, not featured evidence
show 7 more results
78 score @ 12wk
NCT00539071 · Phase 4 · registry result, not featured evidence
74 score @ 18wk
NCT00539071 · Phase 4 · registry result, not featured evidence
72 score @ 24wk
NCT00539071 · Phase 4 · registry result, not featured evidence
-38.37 score @ 26wk
NCT00216671 · Phase 4 · registry result, not featured evidence
-27.48 score @ 6wk
NCT00216671 · Phase 4 · registry result, not featured evidence
-35.84 score @ 12wk
NCT00216671 · Phase 4 · registry result, not featured evidence
18.24 score @ 96wk
NCT00269919 · Phase 4 · registry result, not featured evidence
PANSS Positive 21.4 score @ 6wk
absolute change · score
No placebo or comparator arm
PANSS Positive 6 Weeks
NCT00539071 · Phase 4 · registry result, not featured evidence
PANSS Positive 20 score @ 12wk
absolute change · score
No placebo or comparator arm
PANSS Positive 12 Weeks
NCT00539071 · Phase 4 · registry result, not featured evidence
PANSS Positive 19.1 score @ 18wk
absolute change · score
No placebo or comparator arm
PANSS Positive 18 Weeks
NCT00539071 · Phase 4 · registry result, not featured evidence

+ 33 further endpoints in the CSV export.

Bipolar Disorder

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Bipolar Disordersmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Risperidone (Risperdal Consta)

Marketed by Johnson & Johnson

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.

Risperidone (Risperdal Consta): no structured comparison results are available for Bipolar Disorder.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Risperidone (Risperdal Consta)'s landscape